echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Official: monitoring drug use in public hospitals

    Official: monitoring drug use in public hospitals

    • Last Update: 2019-11-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    First, the local health and Health Committee issued a notice to carry out drug use monitoring in public hospitals On November 18, the office of the Health Committee of Inner Mongolia Autonomous Region issued the notice on the monitoring and analysis of drug use in public medical and health institutions (hereinafter referred to as the notice) According to the notice, according to the relevant requirements of the National Health Commission, all regions need to carry out monitoring and analysis of drug use in medical institutions Inner Mongolia will select medical and health institutions to carry out drug use monitoring and analysis according to the principle of full coverage of three-level public medical and health institutions, 50% of two-level public medical and health institutions and 10% of grass-roots public medical and health institutions Among them, the selected secondary public medical institutions cover all the specialized hospitals, and the grass-roots medical and health institutions evenly select community health service centers and township health centers to cover all the League cities and counties, and the information construction can meet the needs of data submission Inner Mongolia will mainly carry out data monitoring and Analysis on the current drug use directory of selected medical and health institutions, drug allocation and use, diagnosis and treatment drug use information, etc from 2016 to the end of November 2019 According to the notice, it is required to complete the summary analysis and submission of information data of Inner Mongolia by December 25 According to the notice issued by Inner Mongolia health and Health Commission, for drug monitoring in public hospitals, relevant state departments will also officially issue the implementation plan On April 9 this year, the Department of drug policy and basic drug system of the national health and Health Commission issued the notice of the national health and Health Commission on the implementation of drug use monitoring and clinical comprehensive evaluation In the notice, the national health and Health Commission pointed out that drug use monitoring and clinical comprehensive evaluation are the basic work to promote drug return to clinical value, and are important measures to consolidate and improve the basic drug system In the notice, the national health and Health Commission required that the monitoring of drug use be carried out as a whole, and all public medical and health institutions actively cooperated as required to systematically collect and report information such as drug allocation varieties, production enterprises, quantity used, purchase price, supply and distribution At the same time, no less than 1500 public medical and health institutions at all levels in the country were selected to monitor the specific data related to drug use, disease prevention, follow-up and follow-up on the basis of comprehensive monitoring In 2019, the first phase of the national health insurance information project pilot provinces, pilot cities for centralized drug purchase organized by the state, and key monitoring medical and health institutions in each province (District, city) should focus on the national basic drugs, special drugs for anti-cancer drug price reduction and pilot varieties for centralized drug purchase organized by the state, and carry out drug use monitoring as required In 2020, the monitoring scope will basically cover public medical institutions at or above the second level, and extend to grass-roots medical and health institutions, gradually realizing the monitoring of all equipped and used drugs We will encourage social medical institutions and retail pharmacies to voluntarily participate in drug use monitoring On the basis of comprehensive monitoring, the national health and Health Commission requires the administrative departments of health and health at all levels and medical and health institutions to strengthen the analysis and utilization of monitoring information According to the actual allocation and use of drugs in medical institutions, it analyzes the structure of drug use categories, the use of basic drugs and non basic drugs, the use of generic drugs and original research drugs, the change of purchase price, and the payment and reimbursement of drugs Bed comprehensive evaluation provides basic information, and guides the connection between drug purchase of medical institutions and drug use of superior and subordinate medical institutions On the basis of data analysis and in-depth mining, regular monitoring reports shall be formed, communication and coordination with industry and information technology, medical insurance, drug supervision and other departments and drug centralized purchasing agencies shall be strengthened, data and information co construction, sharing and sharing shall be strengthened, drug supply shall be continuously and effectively guaranteed, and "three medical" linkage shall be better promoted In addition, the safety, effectiveness and economy of drug clinical use can also be comprehensively evaluated by drug use monitoring The notice requires medical and health institutions at all levels to make full use of the monitoring data of drug use when carrying out the comprehensive clinical evaluation of drugs, and take the evaluation results as an important basis for the formulation of the drug purchase catalogue, the rational clinical use of drugs, the provision of pharmaceutical services, and the control of unreasonable drug expenses The administrative departments of health and health at all levels should make scientific use of the results of clinical comprehensive evaluation of drugs, strengthen communication and sharing with medical insurance, drug supervision and other departments, promote the improvement of drug policies such as drug research and development, production, circulation and use, and improve the drug supply guarantee system.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.